drugset / Trial / NCT03447951
A Study of PTS100 in Primary HCC Patients
NaSingle-groupOpen-labelTreatment
Summary
This study is being performed to evaluate the efficacy and safety of 30% PTS100 of total tumor volume as intra-tumoral injection therapy in primary Hepatocellular Carcinoma patients who are ineligible for operation or local regional therapy.
Timeline
- Start
- 2018-06-19
- Primary completion
- 2024-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | P-TOLUENESULFONAMIDE | Small molecule | 30 % | Other |